Why the study?
What are the current strategies for the prevention and treatment of viral diarrhea in pediatric patients?
What are the current strategies for the prevention and treatment of viral diarrhea in pediatric patients?
Rotavirus vaccines are highly effective in reducing morbidity from viral diarrhea in children, though treatment for viral gastroenteritis remains primarily symptomatic.
Answers are grounded in this paper and cite their sources.
Supports rotavirus vaccination in endemic regions; extends observational data but leaves non-rotavirus diarrhea management unchanged.
Diarrhea is the second largest cause of mortality worldwide in children from the perinatal period to the age of 5 years. Rotavirus has been the most commonly identified viral cause of diarrhea in children. Norovirus is now recognized as the second most common viral pathogen. Adenovirus, astrovirus and sapovirus are the other major viral causes of pediatric gastroenteritis. Strategies for prevention include basic hygiene, optimization of nutrition and, ultimately, vaccination. Two new vaccines have recently been licensed for the prevention of rotavirus, the monovalent human rotavirus vaccine (Rotarix) and the pentavalent bovine-human reassortant vaccine (RotaTeq). These vaccines have already dramatically decreased the morbidity associated with rotavirus in countries where they are widely used. Efforts to develop a norovirus vaccine face substantial hurdles. Treatment of the viral pathogens is primarily limited to symptomatic measures.
No takes yet. Share an insight, caveat, or question.
Evan J. Anderson (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: